此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Immune Benefits of Coffee

2015年11月30日 更新者:Daniel Bunout、University of Chile

Effect of Coffee Consumption on Immune and Inflammatory Status in Elderly

This study will assess whether coffee consumption:

  • increases immune responses
  • decreases inflammatory status

研究概览

详细说明

Epidemiological studies suggest that coffee consumption is associated with protective effects against several types of chronic diseases. Recent data have shown that certain coffee components may possess anti-inflammatory and immune-enhancing properties. Low-grade inflammation and poor capacity of immune response is highly prevalent in elderly subjects.

The purpose of this study is to evaluate whether coffee consumption improves immune and inflammatory status in healthy elderly subjects. To sort out the role of antioxidants, we will test 2 different soluble coffee, i.e. fully torrefied coffee and partially torrefied coffee.

研究类型

介入性

注册 (实际的)

116

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Metropolitana
      • Santiago、Metropolitana、智利、7830489
        • INTA University of Chile

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

65年 至 90年 (年长者)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Healthy, self-sufficient, free-living Chilean elderly
  • Having the ability to comprehend the procedures of the study
  • Having obtained his/her informed consent after verbal and written information

Exclusion Criteria:

  • Subjects drinking more than 2 cups of coffee per day
  • Subjects with rapidly deteriorating health status at enrolment in the study
  • Subjects with terminal or acute disease, or unstable health status
  • Subjects with chronic disease: chronic respiratory illness; chronic diseases of the pulmonary or cardiovascular systems (including asthma); chronic metabolic disease (diabetes); chronic renal disease, organ failure
  • Subjects with serious neurological disorder, including dementia (MMSE < 20) or Alzheimer's disease
  • Subjects who have experienced rapid weight loss, chronic diarrhea (loose stools, 3 times daily), or Crohn's (IBD)
  • Subjects with gastrointestinal problems
  • Subjects with a hospitalization planned during this study
  • Subjects who have received any antibiotic treatment during the last 3 months prior to the beginning of this study
  • Subjects who had a colonoscopy performed during the last 3 months prior to the beginning of this study
  • Subjects with immune deficiency diseases (e.g. HIV infection)
  • Subjects with a history of allergy - especially to egg protein, egg, shellfish or the antibiotics polymyxin or neomycin
  • Subjects receiving medication that may influence the immune system (i.e. corticosteroids, immuno-suppressors and immuno-modulators, antimicrobials)
  • Subjects who have received any vaccination during the last 15 days prior to baseline
  • Subjects who are expected to be non-compliant
  • Subjects currently participating or having participated in another clinical trial during the last 3 months prior to the beginning of this study
  • Subjects participating in another research study involving any type of medication related to the study

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
无干预:Control
No coffee
实验性的:Group 1
Fully torrefied coffee
Fully torrefied coffee
实验性的:Group 2
Partially torrefied coffee
Partially torrefied coffee

研究衡量的是什么?

主要结果指标

结果测量
大体时间
NK-cell activity
大体时间:will be measured before and after 30 days +/- treatment
will be measured before and after 30 days +/- treatment
Tuberculin test
大体时间:will be measured before and after 30 days +/- treatment
will be measured before and after 30 days +/- treatment
Inflammatory status
大体时间:will be measured before and after 30 days +/- treatment
will be measured before and after 30 days +/- treatment

次要结果测量

结果测量
大体时间
Gut microbiota profiling
大体时间:will be measured before and after 30 days +/- treatment
will be measured before and after 30 days +/- treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Daniel Bunout, MD、INTA University of Chile, Santiago, Metropolitana, Chile

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2009年3月1日

初级完成 (实际的)

2009年5月1日

研究完成 (实际的)

2010年2月1日

研究注册日期

首次提交

2009年3月11日

首先提交符合 QC 标准的

2009年3月11日

首次发布 (估计)

2009年3月12日

研究记录更新

最后更新发布 (估计)

2015年12月2日

上次提交的符合 QC 标准的更新

2015年11月30日

最后验证

2015年11月1日

更多信息

与本研究相关的术语

其他相关的 MeSH 术语

其他研究编号

  • immunecoffee

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅